BioNTech cancer trial misses progression-free survival endpoint

October 13, 2026 6:45 AM

BioNTech SE (NASDAQ: BNTX) announced that its AHEAD-MERIT Phase 2/3 clinical trial for the investigational mRNA cancer immunotherapy BNT113 did ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found